Display options
Cite
Li W, Tang YX, Wan L, et al. Effects of combining Taxol and cyclooxygenase inhibitors on the angiogenesis and apoptosis in human ovarian cancer xenografts. Oncol Lett. 2012;5(3):923-928doi: 10.3892/ol.2012.1086.
Li, W., Tang, Y. X., Wan, L., Cai, J. H., & Zhang, J. (2013). Effects of combining Taxol and cyclooxygenase inhibitors on the angiogenesis and apoptosis in human ovarian cancer xenografts. Oncology letters, 5(3), 923-928. https://doi.org/10.3892/ol.2012.1086
Li, Wei, et al. "Effects of combining Taxol and cyclooxygenase inhibitors on the angiogenesis and apoptosis in human ovarian cancer xenografts." Oncology letters vol. 5,3 (2013): 923-928. doi: https://doi.org/10.3892/ol.2012.1086
Li W, Tang YX, Wan L, Cai JH, Zhang J. Effects of combining Taxol and cyclooxygenase inhibitors on the angiogenesis and apoptosis in human ovarian cancer xenografts. Oncol Lett. 2013 Mar;5(3):923-928. doi: 10.3892/ol.2012.1086. Epub 2012 Dec 19. PMID: 23426648; PMCID: PMC3576189.
Copy Download .nbib Format: NLM
Share it on

Oncol Lett. 2013 Mar;5(3):923-928. doi: 10.3892/ol.2012.1086. Epub 2012 Dec 19.

Effects of combining Taxol and cyclooxygenase inhibitors on the angiogenesis and apoptosis in human ovarian cancer xenografts.

Oncology letters

Wei Li, Yun-Xian Tang, Liang Wan, Jia-Hui Cai, Jun Zhang

Affiliations

  1. Department of Gynecology, Nanjing Medical University of Hangzhou Hospital, Hangzhou, Zhejiang 310006, P.R. China.

PMID: 23426648 PMCID: PMC3576189 DOI: 10.3892/ol.2012.1086

Abstract

The present study aimed to investigate the combined effects of Taxol and cyclooxygenase (COX) inhibitors on angiogenesis and cell apoptosis of SKOV-3 human ovarian carcinoma cell xenograft-bearing mice. The experiments were continued for 28 days. Animals were treated with 3 mg/kg SC-560 (a COX-1-selective inhibitor) alone, 100 mg/kg celecoxib (a COX-2-selective inhibitor) alone or SC-560/celecoxib by gavage twice a day, 20 mg/kg Taxol alone intraperitoneally once a week or in combination with SC-560 or celecoxib or SC-560/celecoxib/Taxol for three weeks. The mRNA levels of vascular endothelial growth factor (VEGF) was determined by reverse transcription-polymerase chain reaction (RT-PCR). The microvessel density (MVD) of ovarian carcinoma was determined by immunohistochemistry with anti-CD(34) as the label. The apoptotic index was detected by the terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling (TUNEL) method. The MVD value and apoptotic index in the SC-560/Taxol group were notably inhibited compared with the Taxol group (P<0.001). Moreover, the VEGF mRNA levels, MVD value and apoptotic index in the SC-560/Taxol group were significantly different from the celecoxib/Taxol group (P<0.05, P<0.05 and P<0.001, respectively). The present study demonstrated that SC-560 enhances the anti-angiogenic and pro-apoptotic effects of Taxol and these effects are better than with celecoxib.

Keywords: SC-560; Taxol; celecoxib; cell apoptosis; microvessel density; ovarian cancer; vascular endothelial growth factor

References

  1. Cancer Res. 2002 Feb 1;62(3):625-31 - PubMed
  2. Anticancer Res. 2001 May-Jun;21(3C):2141-7 - PubMed
  3. J Natl Cancer Inst. 2002 Dec 4;94(23):1745-57 - PubMed
  4. Eur J Gynaecol Oncol. 1999;20(5-6):361-6 - PubMed
  5. J Biol Chem. 2000 May 19;275(20):14838-45 - PubMed
  6. Int J Clin Lab Res. 1994;24(1):6-14 - PubMed
  7. J Clin Oncol. 2003 Jul 15;21(14):2645-50 - PubMed
  8. Pathol Res Pract. 2008;204(4):241-9 - PubMed
  9. J Histochem Cytochem. 1998 Jan;46(1):77-84 - PubMed
  10. Carcinogenesis. 2004 Mar;25(3):349-57 - PubMed
  11. J Clin Oncol. 2002 Mar 1;20(5):1161-3 - PubMed
  12. J Clin Oncol. 2011 Sep 20;29(27):3628-35 - PubMed
  13. Clin Cancer Res. 2009 Mar 15;15(6):2158-65 - PubMed
  14. Cancer. 2010 Apr 1;116(7):1751-6 - PubMed
  15. Cancer Res. 2003 Mar 1;63(5):906-11 - PubMed
  16. N Engl J Med. 1991 Jan 3;324(1):1-8 - PubMed
  17. Semin Oncol. 2002 Feb;29(1 Suppl 1):32-42 - PubMed
  18. Pharmacotherapy. 1994 Jan-Feb;14(1):3-34 - PubMed
  19. Cytokine. 2011 Nov;56(2):365-75 - PubMed
  20. Cancer J. 2005 May-Jun;11(3):209-16 - PubMed
  21. Cancer Res. 2005 May 1;65(9):3735-44 - PubMed
  22. Int J Cancer. 2004 Apr 20;109(4):576-80 - PubMed
  23. J Immunol. 1984 Oct;133(4):1710-5 - PubMed
  24. Int J Cancer. 2010 Jan 15;126(2):382-94 - PubMed
  25. Cancer Res. 2000 Mar 1;60(5):1306-11 - PubMed
  26. Cancer Res. 2000 Nov 1;60(21):6045-51 - PubMed
  27. Int J Mol Sci. 2011 Jan 18;12(1):668-81 - PubMed
  28. Head Neck. 2001 May;23(5):409-25 - PubMed
  29. Nat Rev Drug Discov. 2007 Apr;6(4):273-86 - PubMed
  30. Cancer Res. 2006 Mar 1;66(5):2527-31 - PubMed
  31. Cancer Invest. 2008 Oct;26(8):822-9 - PubMed
  32. Int J Cancer. 2005 Jan 20;113(3):490-8 - PubMed
  33. Curr Pharm Des. 2004;10(6):647-57 - PubMed
  34. J Thorac Oncol. 2011 Jun;6(6):1121-7 - PubMed
  35. Int J Cancer. 1991 Jan 2;47(1):38-43 - PubMed
  36. Med Oncol. 2009;26(2):170-7 - PubMed
  37. Cancer Res. 2007 Jun 1;67(11):5285-92 - PubMed
  38. J Natl Cancer Inst. 1992 Dec 16;84(24):1875-87 - PubMed
  39. Nature. 2000 Sep 14;407(6801):249-57 - PubMed
  40. BMC Cancer. 2006 Jul 11;6:182 - PubMed
  41. Biomed Pharmacother. 2005 Oct;59 Suppl 2:S306-10 - PubMed
  42. Br J Cancer. 1997;76(9):1221-7 - PubMed

Publication Types